FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
-bli-sti-sti-s- C	

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Arnold Charlotte C.						Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP] 3. Date of Earliest Transaction (Month/Day/Year) 08/28/2013									all app Direc	olicable)	10%	Person(s) to Issuer 10% Owner Other (specify	
	(First) (Middle) AIN STREET WEST II PHARMACEUTICALS, INC.														below) `		below)		
(Street) BAUDETTE MN 56623 (City) (State) (Zip)				_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X						
		Tab	le I - N	on-Deriv	<i>r</i> ative	Sec	uritie	s Ac	quire	d, Di	sposed o	of, or E	Benefic	ially (Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,			Code (Insti			s Acquired (A) or If (D) (Instr. 3, 4 a		d 5)	Secur Benef Owne	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D) Price			Reported Transaction(s) (Instr. 3 and 4)			(11150.4)	
Common Stock, par value \$0.0001 08/28/20					2013	13			A ⁽¹⁾		3,675	A	A (1)		3,675		D		
Common Stock, par value \$0.0001 08/28/20					2013	013		F ⁽²⁾		1,364	D \$7.0835		335 ⁽²⁾	5 ⁽²⁾ 2,311		D			
		Ta	able II								osed of, convertib				vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Exerc tion D n/Day/`		Amour Securi Underl Deriva	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ice of vative ırity r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. Represents a portion of the shares to be received by the Reporting Person under a Transaction Bonus Agreement with ANIP Acquisition Company, which portion was released to the Reporting Person from a
- 2. Represents sales effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2013, the proceeds of which are used to pay the required tax withholding amount on the shares released from the rabbi trust. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.92 to \$7.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by her at each separate price on each date of sale.

/s/ Paul A. Gajer, as attorney in 08/30/2013 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.